Edit concept Question Editor Create issue ticket

Filgrastim


Presentation

  • Abstract Bronchiolitis obliterans organizing pneumonia (BOOP) presents with fever, dyspnoea, pleuritic chest pain and hypoxia.[ncbi.nlm.nih.gov]
  • Other hematological parameters are presented in Table III.[spandidos-publications.com]
Retinal Hemorrhage
  • This was complicated by marked hyperleukocytosis and retinal hemorrhages. The patient's symptoms improved gradually following leukopheresis.[ncbi.nlm.nih.gov]
Corneal Infiltrate
  • One week after starting therapy with intravenous filgrastim, a 66-year-old woman developed bilateral keratitis, evidenced by epithelial defects and peripheral corneal infiltrates.[ncbi.nlm.nih.gov]

Workup

  • Serologic workup was negative for anti-nuclear antibody, antistreptococcal antibodies, hepatitis B and C, ANCA, and antiglomerular basement membrane antibodies.[jasn.asnjournals.org]
Alanine Aminotransferase Increased
  • Observed adverse drug reactions with an incidence of 5% were back pain (60.6%), bone pain (9.6%), alanine aminotransferase increase (8.7%), aspartate aminotransferase increase (5.8%) and arthralgia (5.8%).[ncbi.nlm.nih.gov]

Treatment

  • The patients received long-term combination treatment with clozapine and filgrastim.[ncbi.nlm.nih.gov]

Prognosis

  • To determine the effect of r-metHu granulocyte colony-stimulating factor (G-CSF) on the proportion of patients with metastatic poor-prognosis malignant germ cell tumors who receive full dose-intensity combination chemotherapy.[jco.ascopubs.org]
  • […] with a chemotherapy regimen that carries a 20 per cent risk of febrile neutropenia, elderly and frail patients at increased risk, and patients undergoing high-intensity chemotherapy schedules or where delays in treatment are known adversely to affect prognosis[pharmaceutical-journal.com]
  • Champlin Article Figures/Media 25 References 51 Citing Articles Letters Abstract Background Patients whose leukemia relapses after allogeneic bone marrow transplantation have a poor prognosis; few respond to further chemotherapy, and almost none survive[nejm.org]
  • This may have a negative impact on its effectiveness and worsen patient prognosis.[spandidos-publications.com]
  • Patients diagnosed with AML have a relatively poor prognosis, with a 5-year survival rate of about 20%, 8 although various prognostic factors affect the probability of response to chemotherapy and survival. 2 Since the life expectancy for patients with[nature.com]

Etiology

  • ., c-reactive protein and white blood cell count) Consider aortitis in patients who develop these signs and symptoms without known etiology. Discontinue NEUPOGEN if aortitis is suspected.[neupogenhcp.com]
  • Consider aortitis in patients who develop these signs and symptoms without known etiology. Discontinue NIVESTYM TM if aortitis is suspected.[pfizerpro.com]
  • Our patient, previously asymptomatic with respect to sickling (other than back pain of uncertain etiology), developed this syndrome concomitant with the introduction of G-CSF.[bloodjournal.org]

Epidemiology

  • Author information 1 Department of Medical Oncology, University Hospital Zurich, Zurich, Switzerland. 2 Department of Biostatistics, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland. 3 Department of Hematology[ncbi.nlm.nih.gov]
  • We thank Robert Ball, MD, MPH, ScM, and Michael Blum, MD, MPH, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, for critical review of this manuscript.[jamanetwork.com]
  • Approved in the EU Oct 13 [4] Category Pharmacology Immunostimulating medicinal product (L03AA02) which regulates the production and release of functional neutrophils from the bone marrow Epidemiology The incidence of drug-induced neutropenia is one case[sps.nhs.uk]
  • Materials and methods Study design This was a multicenter, non-interventional, real-life, epidemiological study sponsored by Accord Healthcare Polska (Warsaw, Poland), which involved an electronic questionnaire.[spandidos-publications.com]
  • Sanz Department of Internal Medicine, University of Vienna, Vienna, Austria K Lechner Department of Haematology, University of Ghent, Ghent, Belgium L Noens Clinical Haematology, Royal Melbourne Hospital, Melbourne, Australia J Szer Biostatistics and Epidemiology[nature.com]
Sex distribution
Age distribution

Pathophysiology

  • This report explores the spectrum of GN with monoclonal IgG deposits and the pathophysiologic role of granulocyte colony-stimulating factor in exacerbation of preexisting GN.[ncbi.nlm.nih.gov]
  • Pending a better understanding of the pathophysiology of vaso-occlusion, patients with sickle cell disease should receive G-CSF with great caution. Copyright 2001 The American Society of Hematology References Abboud M, Laver J, Blau C-A.[bloodjournal.org]
  • The pathophysiology of this injury may be attributed to the cytokine nature of G-CSF. [2] As the trough tacrolimus levels are within acceptable limits, with no histopathological features of CNI toxicity, it is unlikely that the ATI is related to the CNI[sjkdt.org]
  • This report explores the spectrum of GN with monoclonal IgG deposits and the pathophysiologic role of granulocyte colony–stimulating factor in exacerbation of preexisting GN. glomerulonephritis kidney biopsy paraprotein Proliferative GN with monoclonal[jasn.asnjournals.org]

Prevention

  • Recently, Nivestim , a biosimilar of reference of filgrastim, was approved for prevention of chemotherapy-related febrile neutropenia (FN).[ncbi.nlm.nih.gov]
  • […] it as secondary prevention.[spandidos-publications.com]
  • Nivestim(TM), a New Biosimilar Filgrastim, is Approved in Europe for the Prevention of Febrile Neutropenia Associated With Chemotherapy - Nivestim(TM), Hospira's filgrastim, has received approval from the European Commission (EC) for the prevention of[fiercebiotech.com]

Ask Question

5000 Characters left Format the text using: # Heading, **bold**, _italic_. HTML code is not allowed.
By publishing this question you agree to the TOS and Privacy policy.
• Use a precise title for your question.
• Ask a specific question and provide age, sex, symptoms, type and duration of treatment.
• Respect your own and other people's privacy, never post full names or contact information.
• Inappropriate questions will be deleted.
• In urgent cases contact a physician, visit a hospital or call an emergency service!